Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

LIVE WEBCAST: Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast Cancer

LIVE WEBCAST: Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast Cancer


Wednesday, December 12, 2018
3:00 pm ‒ 4:00 pm EST

Activity Overview

We are pleased to present this CME-certified activity, a PER Live Tumor Board titled, Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast Cancer, accompanied by online enduring activities.

This program updates oncology healthcare professionals who participate in the multidisciplinary treatment of patients with estrogen receptor–positive (ER+) metastatic breast cancer by providing expert guidance, interpretation, and insight on the importance and impact of CDK4/6 inhibitors. Unfortunately, current understanding of how to use CDK4/6 inhibitors is generally limited to registrational studies.

Retroactive observational studies on real-world populations will aid clinicians in understanding how concepts such as dose adjustments and adverse event management are performed in patient populations not part of the original clinical trials that drug approvals were based on. This activity incorporates recent real-world data to ensure that clinicians maintain state-of-the-art treatment practices.

Benefits of Attending

  • Place practice-changing data into its proper clinical context
  • Network with top clinicians and scientists
  • Apply novel management strategies to your practice to improve patient outcomes
  • Participate in an exciting case-based format about current challenges and controversies in the treatment of ER+ breast cancer
  • Incorporate evolving treatment paradigms in the setting of ER+ breast cancer
  • Update your clinical decision-making based upon individual patient/tumor characteristics

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.

Learning Objectives

After participating in this activity, you should be better prepared to:

  • Evaluate results from studies of CDK4/6 inhibitory therapies for the treatment of metastatic breast cancer, including evidence generated from randomized clinical trials and real-world data analyses
  • Integrate evidence from clinically-relevant randomized trials and real-world data analyses of CDK4/6 inhibitor therapies for metastatic breast cancer into existing and emerging management strategies
  • Incorporate key insights, and strategies derived from real world evidence into the mitigation and management of predictable treatment-related toxicities in the management of metastatic breast cancer

Chair

Hope S. Rugo, MD, FASCOHope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA




Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
30
Filter By